Results 161 to 170 of about 380,997 (339)

Partial nephrectomy for presumed renal cell carcinoma: Incidence, predictors, and perioperative outcomes of benign lesions [PDF]

open access: yes, 2017
Bauman, Tyler M   +5 more
core   +2 more sources

Focal Spot, Commemorative Issue, 1996 [PDF]

open access: yes, 1996
https://digitalcommons.wustl.edu/focal_spot_archives/1074/thumbnail ...

core   +1 more source

Mapping Dental Care for Children and Adolescents With Rare Diseases: A Brazilian Multicentre Study

open access: yesCommunity Dentistry and Oral Epidemiology, EarlyView.
ABSTRACT Objectives To describe the landscape of dental care provided by specialised centres for children and adolescents with rare diseases (RDs) in the state of Minas Gerais, southeastern Brazil. Methods A retrospective cross‐sectional study was conducted involving individuals aged 0–18 years with a confirmed diagnosis of a RD who received care at ...
Heloisa Vieira Prado   +21 more
wiley   +1 more source

Prevalence and Spectrum of Congenital Heart Disease in Individuals With Distal Chromosome 22q11.22–23 Deletions

open access: yesClinical Genetics, EarlyView.
The frequency and severity of congenital heart disease vary extensively in individuals with 22q11.22–23 distal deletions. Reduced gene dosage particularly within the low copy repeat (LCR22) D–E region including MAPK1 and HIC2 conveys risk for these defects.
Tanner J. Nelson   +22 more
wiley   +1 more source

Rethinking Gleason pattern quantification in predicting metastasis: results of 20 years of follow‐up in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer

open access: yesHistopathology, EarlyView.
Example of prostate biopsy absolute lengths and proportions, and their impact on ISUP Grade Group assessment. While the absolute length of Gleason pattern 4 in all three pictured biopsies is the same (3 mm), the absolute length of Gleason pattern 3 differs, which leads to counter‐intuitive proportion‐based Grade Groups.
Lisa J Kroon   +7 more
wiley   +1 more source

Papillary renal cell carcinoma, formerly known as Type 2: a single institutional study addressing histologic and molecular features

open access: yesHistopathology, EarlyView.
Papillary renal cell carcinoma (pRCC) accounts for 15%–20% of RCC cases and is the second most common histologic subtype of RCC. In contrast to other common RCC subtypes, there continues to be ongoing debate about how to classify RCCs with papillary architecture and eosinophilic cytoplasm, given the heterogeneity of histologic, IHC and molecular ...
Melissa Yuwono Tjota   +3 more
wiley   +1 more source

Diagnosing oncocytic renal tumours on renal mass biopsy; pathological concordance and the impact of evolving classification

open access: yesHistopathology, EarlyView.
Overall, there was good concordance between renal mass biopsy and subsequent diagnosis at nephrectomy or repeat biopsy in oncocytic renal neoplasms. Some discordant cases were reclassified as emerging tumour entities (LOT, EVT), indicating that greater recognition of these entities may help reduce diagnostic uncertainty and improve biopsy ...
Shifaa' Al Qa'qa'   +4 more
wiley   +1 more source

A minor high‐grade component in non‐invasive papillary urothelial carcinoma is not associated with a more indolent behaviour

open access: yesHistopathology, EarlyView.
Non‐invasive papillary urothelial carcinomas with minor high‐grade component are not associated with a more indolent behavior and should likely be regarded as high‐grade carcinomas. Aims The latest WHO edition proposed using a cut‐off of ≥5% high‐grade component (%HGc) as a criterion to label non‐invasive papillary urothelial carcinomas as high‐grade ...
Mina S. Farag   +5 more
wiley   +1 more source

Enfortumab vedotin plus pembrolizumab in treatment‐naïve metastatic urothelial carcinoma patients: An Austrian real‐world analysis

open access: yesInternational Journal of Cancer, Volume 158, Issue 6, Page 1654-1665, 15 March 2026.
What's new? New antibody‐drug conjugates (ADCs) and immunotherapies have helped expand treatment options for urothelial carcinoma (UC). Clinical trials suggest that the ADC enfortumab vedotin (EV) and the immunotherapeutic agent pembrolizumab, when used in combination, are especially effective against UC.
Dora Niedersuess‐Beke   +30 more
wiley   +1 more source

Home - About - Disclaimer - Privacy